WEC
RIGL icon

Winslow Evans & Crocker’s Rigel Pharmaceuticals RIGL Stock Holding History

Winslow Evans & Crocker’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-350
Closed -$6K – 1163
2020
Q1 		$6K Hold
350
– – ﹤0.01% 835
2019
Q4 		$8K Hold
350
– – ﹤0.01% 885
2019
Q3 		$8K Buy
+350
New +$7.23K ﹤0.01% 872

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Winslow Evans & Crocker's RIGL Position: Q2 2020 in Review

Winslow Evans & Crocker sold out of Rigel Pharmaceuticals (RIGL) in Q2 2020, closing a stake of 350 shares — an estimated $6K sold.

Winslow Evans & Crocker first reported a position in RIGL in Q3 2019 and held it in 3 quarters. The position peaked at $8K in Q4 2019. 135 funds tracked by Wall St. Rank hold RIGL as of Q2 2020.

  • Winslow Evans & Crocker reported no remaining Rigel Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Winslow Evans & Crocker sold 350 Rigel Pharmaceuticals shares in Q2 2020, an estimated $6K.
  • Winslow Evans & Crocker first reported a position in Rigel Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Winslow Evans & Crocker's Rigel Pharmaceuticals position peaked at $8K in Q4 2019.
  • 135 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2020.

Based on Winslow Evans & Crocker's 13F filing for Q2 2020, filed 23 Jul 2020.